GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update

GANX

Gain Therapeutics reported financial results for the quarter ended September 30, 2026, alongside corporate \& pipeline updates.
Long-term open-label data from the Phase 1b trial of rexaceract in Parkinson's disease showed no motor symptom progression after 12 months of dosing.
Participants with both high \& low baseline levels of glucosylsphingosine demonstrated stabilized MDS-UPDRS motor scores with no clinically meaningful progression.
Rexaceract was generally well tolerated over 12 months with no new safety signals \& a lower incidence of treatment-emergent adverse events in the extension phase.
Perceived benefits included improved sense of smell, taste, balance, gait, \& sleep among trial participants.
The Phase 2 clinical trial for rexaceract is expected to initiate in Q1 2027 following protocol redesign \& updates in Q4 2026.
Gain plans to select an initial therapeutic indication to advance its second candidate, GT-04686, into the clinic in Q4 2026.
Jeanette Weidner was appointed as Vice President, Finance, to support strategic operations.
Research \& development expenses decreased by $1.4 million to $1.4 million in Q3 2026 due to lower costs for rexaceract, pipeline optimization, \& personnel expenses.
General \& administrative expenses decreased by $0.1 million to $1.8 million in Q3 2026 primarily due to lower professional fees \& personnel costs.
Net loss for the three months ended September 30, 2026, was $0.07 per share, compared to $0.15 per share in the same period of 2025.
Cash \& cash equivalents totaled $11.7 million as of September 30, 2026, down from $20.8 million as of December 31, 2025.
Rexaceract is a GCase positive allosteric modulator currently in Phase 1b development for Parkinson's disease with or without a GBA1 mutation.
Preclinical data suggests rexaceract may have disease-modifying potential by restoring GCase function \& reducing neurodegeneration markers.

Company: Gain Therapeutics, Inc.
Keywords: Nasdaq:GANX, Gain Therapeutics, Inc.